[PDF] Top 20 Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
Has 10000 "Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia" found on our website. Below are the top 20 most common "Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia".
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
... nM) in other clones of HL60 IDH1 WT (clone 2) or R132H (clone ...gavage in MOLM14 CLDX. In this model, IDH1 R132 mutation or IDH1 WT overexpression is induced by doxycycline (left ...concentration ... Voir le document complet
35
Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
... found in 30% of AML patients and con- fer a poor prognosis with enhanced relapse rate [ 176 – 179 ...kinase inhibitors (TKIs) against the oncogenic kinase BCR-ABL for CML treat- ment raised great ... Voir le document complet
18
Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy
... elevated in several types of tumors, and that USP7 overexpression is often predictive of a poor prognosis [ 9 , 32 , 35 , 36 ...logical inhibitors of this enzyme have recently been developed [ 9 , 13 – 19 ... Voir le document complet
17
Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study.
... important in future studies because these may be more biologically distinct that previously ...patients in this cohort who had chronic myelomonocytic leu- kemia or other MPNs may have had poorer outcomes, ... Voir le document complet
9
Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
... was to assess the prog- nostic impact of BCR‐ABL KD ...tions in late disease phases are one but not the main leukemic evolution ...advantage in BP as recently demonstrated by Jain et al ... Voir le document complet
11
Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the LEA program
... agreed to participate. Among these 218, 185 were treated according to one of the 6 multicenter trial protocols ongoing in France after January ...included in the present ... Voir le document complet
5
Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms
... like 3+7 are used in eligible patients but the response rate is low, toxicity and mortality high with poor long term results 5 . Encouraging results have been obtained with hypomethylating agents but data are ... Voir le document complet
30
Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.
... role in hematopoietic stem cells (HSC) proliferation and differentiation ...MSI2 in mice created a pre-leukemic phase [21] and its overexpression was found during transition from chronic to ... Voir le document complet
10
Analysis of the proteasome-autophagy crosstalk under proteotoxic stress conditions in acute myeloid leukemia
... essential to study the mRNA expression of distinct proteasome subunits in distinct AML cell ...performed in asynchronous cells. This could explain, at least in part, the low percentage of ... Voir le document complet
222
The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs
... pathway in AMLs apoptotic response to chemotherapeutic ...used in the clinic induce rapid ROS- dependent protein desumoylation, which participates both in transcriptome alteration and ... Voir le document complet
10
en fr Mechanisms of resistance to tyrosine kinase inhibitors on the model of chronic myeloid leukemia Mécanismes de résistance aux inhibiteurs de tyrosine kinase sur le modèle de leucémie myéloïde chronique
... mTORC2 qui, de son tour, phosphoryle Akt sur la sérine 473. La phosphorylation d’Akt sur sa thréonine 308, induite par PI3K/PDK1, est nécessaire pour l’activation complète de l’Akt qui ensuite active la voie mTORC1 68 . ... Voir le document complet
111
H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations
... failed to show hallmarks of decreased cellular proliferation or ...GSK-J4 in RUNX1 mut AML cells observed in vitro was most likely due to an off- target effect of ...GSK-J4. In response ... Voir le document complet
89
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
... down to constitute the day 0 time point, and cells were maintained in culture and split every two days to keep at least 6×10 6 cells per replicate until day ...mutations to barcode individual ... Voir le document complet
34
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
... attempted to minimize the possible lim- itations inherent in retrospective registry-based studies by studying a large patient cohort, by double-checking the RIC/ MAC information and by using early NRM as ... Voir le document complet
12
Practical management of Chronic Myeloid Leukemia in Belgium
... compliance in order to achieve the best molecular response with the best quality of ...restricted to clinical ...transformation. In these cases, allogeneic HSCT remains the only curative ... Voir le document complet
17
Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
... PF-06747143 to induce cell death by ADCC on AML primary BM malignant cells, in presence of an NK effector cell line, NK92 158 ...compared to the IgG1 control antibody (Fig. 3A ). In a clini- ... Voir le document complet
14
Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?
... 18,19 In this issue of Bone Marrow Transplantation, Jedlickova et ...DLI in a cohort of 46 high-risk AML patients given grafts following a sequential treatment consisting of chemotherapy (FLAMSA) followed ... Voir le document complet
3
Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials
... Secondary acute myeloid leukemia (sAML) describes patients (pts) with a history of malignant or non-malignant disease or AML secondary to environmental, occupational or therapeutic ... Voir le document complet
3
Understanding the transcriptional control of EIF4E and its dysregulation in acute myeloid leukemia: role of NF-κB
... interesting to determine the importance of each κB site (promoter and intron) in the transcriptional regulation of EIF4E and whether these elements function cooperatively under the investigated ...context. ... Voir le document complet
154
ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
... observed in stem cell transplantation and its impact in this set- ting has been extensively ...outcome in MMURD transplantation for acute myeloid leukemia (AML) patients is ... Voir le document complet
8
Sujets connexes